Matthew Donley is a accomplished pharmaceutical executive with more than 25 years of experience in operations, supply chain management, and strategic growth within the biotechnology sector. He began his career at Bristol-Myers Squibb, where he honed his expertise in global manufacturing and regulatory compliance, eventually leading cross-functional teams to streamline production processes and achieve multimillion-dollar cost reductions. Donley later served in senior roles at Biogen and Alexion Pharmaceuticals, spearheading operational expansions that supported blockbuster drug launches and navigated complex international regulatory landscapes, earning him recognition as a key driver of efficiency and innovation. As Chief Operating Officer at Aurinia Pharmaceuticals Inc. from 2018 to 2023, Donley was instrumental in transforming the company's operations to support the commercialization of LUPKYNIS (voclosporin), the first FDA-approved novel therapy for lupus nephritis in over 20 years. He oversaw the build-out of manufacturing capabilities, supply chain infrastructure, and quality systems, enabling a seamless market launch in the U.S. and Europe while ensuring compliance with stringent FDA and EMA standards. Under his leadership, Aurinia achieved record revenue growth, expanded its commercial footprint, and positioned itself as a leader in rare disease therapeutics. Donley's tenure at Aurinia was marked by notable achievements, including the implementation of advanced digital supply chain technologies that reduced lead times by 40% and enhanced patient access programs. His strategic vision not only fortified the company's operational resilience during the COVID-19 pandemic but also laid the groundwork for future pipeline advancements. Now as former COO, Donley continues to advise biotech firms on scaling operations for precision medicine.